Organon (OGN) Income from Continuing Operations (2020 - 2026)
Organon (OGN) recorded quarterly Income from Continuing Operations of 146000000.0 in Q1 2026, up 171.22% quarter-over-quarter from 205000000.0 in Q4 2025, and up 67.82% on a YoY basis from 87000000.0 in Q1 2025.
Organon (OGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Organon's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 146000000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 67.82% year-over-year to 146000000.0; the TTM figure through Mar 2026 stood at 246000000.0 (down 67.2% YoY), while the FY2025 annual figure was 187000000.0, down 78.36% from the prior year.
- Income from Continuing Operations was 146000000.0 for Q1 2026 at Organon, up from 205000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 546000000.0 in Q4 2023 to a low of 205000000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 210000000.0 across 5 years, with a median of 195000000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 518.97% in 2024, then sank 288.07% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 541000000.0 in 2022, then gained by 0.92% to 546000000.0 in 2023, then plunged by 80.04% to 109000000.0 in 2024, then tumbled by 288.07% to 205000000.0 in 2025, then jumped by 171.22% to 146000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 146000000.0 (Q1 2026), 205000000.0 (Q4 2025), and 160000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 146.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | -205.00 Mn |
| Sep 30, 2025 | 160.00 Mn |
| Jun 30, 2025 | 145.00 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 109.00 Mn |
| Sep 30, 2024 | 359.00 Mn |
| Jun 30, 2024 | 195.00 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 546.00 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 242.00 Mn |
| Mar 31, 2023 | 177.00 Mn |
| Dec 31, 2022 | 541.00 Mn |
| Sep 30, 2022 | 227.00 Mn |
| Jun 30, 2022 | 234.00 Mn |
| Mar 31, 2022 | 348.00 Mn |
| Dec 31, 2021 | 202.00 Mn |
| Sep 30, 2021 | 323.00 Mn |
| Jun 30, 2021 | 431.00 Mn |